Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change
Background Aortic stiffness is an independent predictor of cardiovascular events in patients with arterial hypertension. Resistant hypertension is often linked to hyperaldosteronism and associated with adverse outcomes. Spironolactone, a mineralocorticoid receptor antagonist, has been shown to reduc...
Main Authors: | Sudeep R. Aryal, Mohammed Siddiqui, Oleg F. Sharifov, Megan D. Coffin, Bin Zhang, Krishna K. Gaddam, Himanshu Gupta, Thomas S. Denney, Louis J. Dell'Italia, Suzanne Oparil, David A. Calhoun, Steven G. Lloyd |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.120.019434 |
Similar Items
-
Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism
by: Yu-Fang Lin, et al.
Published: (2020-12-01) -
Analysis of spironolactone polymorphs in active pharmaceutical ingredients and their effect on tablet dissolution profiles
by: Renata Cunha de Resende, et al. -
Spironolactone-Induced Agranulocytosis: A Case Report
by: Shu-Hwa Hsiao, et al.
Published: (2003-11-01) -
Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
by: Yugar-Toledo JC, et al.
Published: (2017-10-01) -
Novel role of spironolactone in the therapy of resistant hypertension: Spironolactone and resistant hypertension
by: Dragojević-Simić Viktorija, et al.
Published: (2019-01-01)